Clinical Trial Detail

NCT ID NCT02759588
Title GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Genelux Corporation
Indications

ovarian clear cell carcinoma

endometrioid ovary carcinoma

ovarian serous carcinoma

ovarian carcinoma

Therapies

GL-ONC1

Age Groups: adult senior

No variant requirements are available.